Conference Coverage
Advertisement
Andrea Riccardo Filippi, MD, presented survival data from the final PACIFIC-R data extraction with over 5 years of follow-up.
Suresh S. Ramalingam, MD, FACP, FASCO, presented the data during a proffered paper session at ELCC 2025.
Marina Garassino, MD, presented results from the phase 2 portion of the trial at the European Lung Cancer Congress.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Myung-Ju Ahn, MD, PhD, presented data from the study during the first proffered paper session of ELCC 2025.
Nicolas Girard, MD, PhD, of Institut Curie, presented the findings from expansion cohorts of the study at ELCC 2025.
Xiuning Le, MD, PhD, presented results from the ORCHARD trial at ELCC 2025.
The award recognizes his "exceptional contributions to thoracic oncology research and education."
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
Dr. Liu shares what he's looking forward to during the European Lung Cancer Congress, which will be held March 26-29.
The NCCN 2025 Annual Conference will be held from March 28-30 in Orlando, Florida.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
Mara B. Antonoff, MD, FACS, discusses what could be on the horizon for surgery in stage IV lung cancer.
Dr. Seder discusses the real-world study he presented at STS 2025, which addressed key questions about long-term outcomes.
Mara B. Antonoff, MD, FACS, shares key considerations and developments in surgery for stage IV lung cancer.
However, the study findings presented at STS 2025 suggest that segmentectomy may be a “viable alternative” to lobectomy.
Rilvegostomig showed a favorable safety profile and encouraging preliminary efficacy in NSCLC.
The results may establish osimertinib as the new standard of care for EGFR-mutated NSCLC in a certain setting.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.